Egrifta FDA Approval History
FDA Approved: Yes (First approved November 10, 2010)
Brand name: Egrifta
Generic name: tesamorelin
Dosage form: Injection
Treatment for: Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy
Egrifta (tesamorelin) is a synthetic analogue of growth hormone releasing factor (GRF) for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Development Timeline for Egrifta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.